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MaBACKGROUND A new scoring system, the anticoagulation and risk factors in atrial ﬁbrillation (ATRIA) score, was
proposed for risk stratiﬁcation in patients with atrial ﬁbrillation (AF). Whether the ATRIA scheme can adequately
identify patients who are at low risk of ischemic stroke remains unknown.
OBJECTIVES The goal of the present study was to compare the performance of ATRIA to that of CHA2DS2-VASc
(congestive heart failure, hypertension, age $75, diabetes mellitus, prior stroke or transient ischemic attack,
vascular disease, age 65 to 74, female) scores for stroke prediction.
METHODS This study used the National Health Insurance research database in Taiwan. A total of 186,570
AF patients without antithrombotic therapy were selected as the study cohort. The clinical endpoint was
the occurrence of ischemic stroke.
RESULTS During the follow-up of 3.4  3.7 years, 23,723 patients (12.7%) experienced ischemic stroke. The
CHA2DS2-VASc score performed better than ATRIA score in predicting ischemic stroke as assessed by c-indexes
(0.698 vs. 0.627, respectively; p < 0.0001). The CHA2DS2-VASc score also improved the net reclassiﬁcation index
by 11.7% compared with ATRIA score (p < 0.0001). Among 73,242 patients categorized as low-risk on the basis of an
ATRIA score of 0 to 5, the CHA2DS2-VASc scores ranged from 0 to 7, and annual stroke rates ranged from 1.06% to
13.33% at 1-year follow-up and from 1.15% to 8.00% at 15-year follow-up. The c-index of CHA2DS2-VASc score
(0.629) was signiﬁcantly higher than that of the ATRIA score (0.593) in this “low-risk” category (p < 0.0001).
CONCLUSIONS Patients categorized as low-risk by use of the ATRIA score were not necessarily low-risk,
and the annual stroke rates can be as high as 2.95% at 1-year follow-up and 2.84% at 15-year follow-up. In
contrast, patients with a CHA2DS2-VASc score of 0 had a truly low risk of ischemic stroke, with an annual stroke
rate of approximately 1%. (J Am Coll Cardiol 2014;64:1658–65) © 2014 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
ATRIA = anticoagulation and
risk factors in atrial ﬁbrillation
CI = conﬁdence interval
CHA2DS2-VASc = congestive
heart failure, hypertension,
age ‡75, diabetes mellitus,
prior stroke or transient
ischemic attack, vascular
disease, age 65 to 74, female
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1659A trial ﬁbrillation (AF) is an important risk fac-tor for ischemic stroke, and AF-related strokehas a worse prognosis and higher recurrence
rate than non-AF-related stroke (1). Stroke prevention
is the cornerstone for AF management, and effective
stroke risk stratiﬁcation is a key step. The current
focus is the initial identiﬁcation of “low risk” AF pa-
tients who do not need antithrombotic therapy, and,
subsequent to this decision step, patients with stroke
risk factor $1 can be offered effective stroke preven-
tion, which is oral anticoagulation (OAC) (2).SEE PAGE 1666
AF patients without use of any
anti-platelet or anti-coagulant agent
(n=186,570)
AF patients older than 20 years 
(n=354,649)
NHIRD cohort (1996-2011)
More than 23 million enrollees
FIGURE 1 Flowchart of Study Cohort Enrollment
From January 1, 1996, to December 31, 2011, a total of 186,570
AF patients who were not receiving oral anticoagulants or
antiplatelet agents were enrolled in this study. AF ¼ atrial
ﬁbrillation; NHIRD ¼ National Health Insurance Research
Database.
eGFR = estimated glomerular
ﬁltration rate
ESRD = end-stage renal
disease
NHI = National Health
Insurance
NRI = net reclassiﬁcation index
OAC = oral anticoagulation
ROC = receiver operating
characteristic curve
TIA = transient ischemic attackThe congestive heart failure, hypertension,
age $75 years, diabetes mellitus, and prior stroke or
transient ischemic attack (TIA) (CHADS2) score has
been commonly used to guide antithrombotic thera-
pies for AF patients since it was proposed and vali-
dated in 2001 (3). However, the annual stroke rate is
still nearly 2% for patients with a CHADS2 score of 0,
and a considerable proportion of patients may be
misclassiﬁed as “low risk” without taking OACs for
stroke prevention, accordingly (4,5). In 2010, the
congestive heart failure, hypertension, age $75, dia-
betes mellitus, prior stroke or transient ischemic
attack, vascular disease, age 65 to 74, female
(CHA2DS2-VASc) score (6) was developed and was
suggested to be better than the CHADS2 score for
identifying truly low-risk patients in several inde-
pendent cohorts (4,7–10).
More recently, another new scoring system, the
anticoagulation and risk factors in atrial ﬁbrillation
(ATRIA) score was proposed (11). This score includes
renal dysfunction (estimated glomerular ﬁltration
rate [eGFR] <45 ml/min or end-stage renal disease
[ESRD]) and proteinuria in the model and requires
different score weighting for primary and secondary
prevention. Developers of the ATRIA scheme re-
ported that the ATRIA score performed statistically
better than the CHADS2 and CHA2DS2-VASc scoring
systems, although the differences in c-indexes were
marginal with some overlap of the 95% conﬁdence
intervals (CI) (11). Also, the percentage of patients
categorized as low-risk by ATRIA score was 46.7%,
comparable to the percentage of low-risk patients
stratiﬁed by CHADS2 score (49.7%). The concern is
raised as to whether the ATRIA score is able to iden-
tify patients with a truly low risk of ischemic stroke.
The goal of the present study was to compare
the predictive accuracies of the CHA2DS2-VASc
and ATRIA scores in predicting ischemic stroke
in a contemporary unselected “real-world” cohort of
nonanticoagulated AF patients from a nationwide
cohort study. We also determined stroke rates inpatients classiﬁed as low-risk by the ATRIA
scheme (score 0 to 5) and ascertained event
rates in these patients in relation to the
CHA2DS2-VASc score. We tested the hypoth-
esis that the CHA2DS2-VASc score would be
better in identifying truly low-risk patients
than the ATRIA score.
METHODS
This study used the National Health Insur-
ance (NHI) research database released by the
Taiwan National Health Research Institutes.
The NHI system is a mandatory universal
health insurance program that offers com-
prehensive medical care coverage to all
Taiwanese residents. The NHI research data-
base consists of detailed health care data from
>23 million enrollees, representing >99% of
Taiwan’s population. In this cohort dataset,
the patients’ original identiﬁcation numbers
were encrypted to protect their privacy, using
a consistent encrypting procedure so that it
was feasible to link and continuously follow all of the
claims belonging to the same patient within the NHI
database. The large sample size of this database
TABLE 1 Baseline Ch
Variable N
Age, yrs
Components of the
CHA2DS2-VASc
score
Congestive heart
failure
7
Hypertension 11
Age $75 yrs 9
Diabetes mellitus 5
Previous stroke/TIA 3
Vascular diseases 2
Age $65 yrs 4
Sex category
(female)
8
CHA2DS2-VASc score
0
1 1
2 26
3 3
4
5 2
6 20
7 1
8
9
Values are n (%) or mean
AF ¼ atrial ﬁbrillation;
congestive heart failure, h
vascular disease, age 65 to
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1660provided a good opportunity to study the risk of
ischemic stroke in AF patients stratiﬁed by CHA2DS2-
VASc and ATRIA scores.
STUDY COHORT. From January 1, 1996, to December
31, 2011, a total of 354,649 AF patients aged 20 years
and older were identiﬁed from the NHI research
database as the study population. AF was diagnosed
using International Classiﬁcation of Diseases, ninth
revision, Clinical Modiﬁcation (ICD-9-CM) codes
(427.31). To ensure diagnostic accuracy, we deﬁned
patients with AF only when it was a discharge diag-
nosis or conﬁrmed more than twice in the outpatient
department. Patients who received treatments with
warfarin or any antiplatelet agent, including aspirin,
clopidogrel, dipyridamole, and ticlopidine, were ex-
cluded from the study population. A total of 186,570
patients were ﬁnally enrolled in the study cohort. A
ﬂowchart of the enrollment of the study cohort is
shown in Figure 1.
CALCULATION OF SCORE AND DEFINITION OF
CLINICAL ENDPOINT. The CHA2DS2-VASc score was
calculated for each patient by assigning 1 point each for
age between 65 and 74 years, history of hypertension,aracteristics of AF Patients by ATRIA Score
Total
¼ 186,570
ATRIA Score
0–5
n ¼ 73,242 (39.3%)
ATRIA Score
6
n ¼ 19,952 (10.7%)
ATRIA Score
7–15
n ¼ 93,376 (50.0%)
72.0  13.9 60.3  12.7 76.7  6.6 80.2  8.5
2,220 (38.7) 15,690 (21.4) 6,352 (31.8) 50,178 (53.7)
7,285 (62.9) 30,071 (41.1) 11,330 (56.8) 75,884 (81.3)
3,980 (50.4) 5,068 (6.9) 12,819 (64.3) 76,093 (81.5)
0,180 (26.9) 10,961 (15.0) 4,325 (21.7) 34,894 (37.4)
8,223 (20.5) 0 (0.0) 0 (0.0) 38,223 (40.9)
8,509 (15.3) 9,292 (12.7) 2,740 (13.7) 16,477 (17.7)
6,868 (25.1) 26,551 (36.3) 6,928 (34.7) 13,389 (14.3)
5,862 (46.0) 25,347 (34.6) 7,968 (39.9) 52,547 (56.3)
9,416 (5.1) 9,416 (12.9) 0 (0.0) 0 (0.0)
9,325 (10.4) 19,325 (26.4) 0 (0.0) 0 (0.0)
,096 (14.0) 22,993 (31.4) 2,187 (11.0) 916 (1.0)
1,272 (16.8) 14,185 (19.4) 9,185 (46.0) 7,902 (8.5)
31,512 (16.9) 5,003 (6.8) 5,014 (25.1) 21,495 (23.0)
7,295 (14.6) 1,840 (2.5) 2,490 (12.5) 22,965 (24.6)
,860 (11.2) 458 (0.6) 846 (4.2) 19,556 (20.9)
3,585 (7.3) 22 (0.0) 230 (1.2) 13,333 (14.3)
5,970 (3.2) 0 (0.0) 0 (0.0) 5,970 (6.4)
1,239 (0.7) 0 (0.0) 0 (0.0) 1,239 (1.3)
 SD.
ATRIA ¼ anticoagulation and risk factors in atrial ﬁbrillation; CHA2DS2-VASc ¼
ypertension, age $75, diabetes mellitus, prior stroke or transient ischemic attack,
74, female; TIA ¼ transient ischemic attack.diabetes, recent cardiac failure, vascular disease
(myocardial infarction or peripheral artery disease),
and female sex, and 2 points each for a history of a
stroke, TIA, or age $75 years (6). The ATRIA score was
calculated for patients with a history of stroke by
assigning 9 points for age $85 years, 7 points for age
between 65 and 84 years, or 8 points for age <65 years
and 1 point each for history of diabetes, congestive
heart failure, hypertension, proteinuria, eGFR<45 ml/
min or ESRD, and female sex (11). For patients without
prior stroke, the ATRIA score was calculated by
assigning 6 points for age $85 years, 5 points for age
between 75 and 84 years, 3 points for age between
65 and 74 years, and 1 point each for history of diabetes,
congestive heart failure, hypertension, proteinuria,
eGFR <45 ml/min or ESRD, and female sex (11). On the
basis of the ATRIA score, the study cohort was strati-
ﬁed into low (0 to 5 points), moderate (6 points), and
high (7 to 15 points) risk categories (11). The ICD-9-CM
codes used to identify risk factor components of
the scoring schemes are shown in Online Table 1.
The clinical endpoint was the occurrence of
ischemic stroke with concomitant imaging studies of
the brain, including computed tomography or mag-
netic resonance imaging. The accuracy of diagnosis of
ischemic stroke in the NHI research database was
validated previously (12).
STATISTICAL ANALYSIS. Data are mean values 
SD for normally distributed continuous variables and
proportions for categorical variables. Differences
between continuous values were assessed using an
unpaired 2-tailed Student t-test for normally
distributed variables and Mann-Whitney rank-sum
test for skewed variables. Differences among nomi-
nal variables were compared by chi-square test.
Ischemic stroke risk was assessed using Cox regres-
sion analysis. The cumulative incidence curve of
ischemic stroke was plotted via the Kaplan-Meier
method, with statistical signiﬁcance examined by
the log-rank test. We assessed the predictive accu-
racies of the ATRIA and CHA2DS2-VASc scores by
calculating c-indexes on the basis of receiver oper-
ating characteristic (ROC) curves. Areas under the
ROC curves for these two scoring systems were
compared using DeLong’s test. The net reclassi-
ﬁcation index (NRI) comparing the ATRIA and
CHA2DS2-VASc scores was also calculated. Statistical
signiﬁcance was deﬁned as a p value of <0.05.
RESULTS
Baseline characteristics of the study cohort are shown
in Table 1. The mean age of patients was 72.0  13.9
years, and 54.0% were male. The median values
1.0
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ATRIA score, AUC = 0.627CHA2DS2-VASc score, AUC = 0.698
FIGURE 2 ROC Curves of CHA2DS2-VASc and ATRIA Scores in
Predicting Ischemic Stroke
The c-indexes on the basis of AUCs for the CHA2DS2-VASc and
ATRIA scores in predicting ischemic stroke were 0.698 and
0.627, respectively (DeLong test, p < 0.0001). ATRIA ¼ anti-
coagulation and risk factors in atrial ﬁbrillation; AUC ¼ area
under the curve; CHA2DS2-VASc ¼ congestive heart failure,
hypertension, age $75, diabetes mellitus, prior stroke or
transient ischemic attack, vascular disease, age 65 to 74,
female; ROC ¼ receiver operating characteristic.
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1661(interquartile range) of the CHA2DS2-VASc and ATRIA
scores were 4 (2 to 5) and 7 (4 to 9), respectively.
Hypertension was the most prevalent comorbidity
and was noted in 62.9% of patients. On the basis of
the ATRIA score, there were 39.3%, 10.7%, and 50.1%
of patients who were classiﬁed as low-risk (0 to 5
points), moderate-risk (6 points), and high-risk (7 to
15 points) groups, respectively.
During the follow-up of 3.4  3.7 years, 23,723 pa-
tients (12.7%) experienced ischemic stroke. Both the
ATRIA and CHA2DS2-VASc scores were signiﬁcant
predictors of ischemic stroke, with a hazard ratio of
1.093 (95% CI: 1.089 to 1.098) and 1.153 (95% CI: 1.146
to 1.161) per 1 increment of the ATRIA and CHA2DS2-
VASc scores, respectively.
Figure 2 shows the ROC curves of ATRIA and
CHA2DS2-VASc scores in predicting ischemic stroke.
The c-indexes on the basis of areas under the ROC
curves for the ATRIA and CHA2DS2-VASc scores in
predicting ischemic stroke were 0.627 (95% CI: 0.620
to 0.635) and 0.698 (95% CI: 0.691 to 0.705), respec-
tively. The difference was statistically signiﬁcant
in favor of the CHA2DS2-VASc score (DeLong test,
p < 0.0001). The CHA2DS2-VASc score also improved
the NRI by 11.7% (95% CI: 9.9% to 13.6%) compared
with the ATRIA score (p < 0.0001).
RISK OF ISCHEMIC STROKE FOR PATIENTS WITH AN
ATRIA SCORE OF 0–5. Among 73,242 patients with
an ATRIA score of 0 to 5, the stroke rate was 2.95
per 100 person-years at 1-year follow-up, 2.75 per
100 person-years at 5-year follow-up, 2.80 per 100
person-years at 10-year follow-up, and 2.84 per 100
person-years at 15-year follow-up (Table 2). For
10,039 patients with an ATRIA score of 0, the annual
event rates at 1-year, 5-year, 10-year, and 15-year
follow-up examinations were 1.28, 1.36, 1.31, and
1.32 per 100 person-years, respectively.
LOW-RISK PATIENTS WITH AN ATRIA SCORE OF
0 TO 5, SUBSTRATIFIED BY CHA2DS2-VASc SCORES.TABLE 2 Event Rate of Ischemic Stroke Per 100 Person-Years in AF P
ATRIA Score
1-Year Follow-Up 5-Year F
Person-Years
No. of
Events
Stroke
Rate Person-Years
0 8,115 104 1.28 36,958
1 13,670 226 1.65 54,513
2 8,415 262 3.11 32,045
3 8,230 270 3.28 30,513
4 10,343 394 3.81 37,773
5 14,313 603 4.20 46,377
Total patients 63,086 1,859 2.95 238,179
Abbreviations as in Table 1.Among patients with an ATRIA score of 0 to 5, the
CHA2DS2-VASc scores of these subjects ranged from
0 to 7. Kaplan-Meier estimates of the probability
of remaining free of ischemic stroke according to
the CHA2DS2-VASc score are illustrated in Figure 3.
Even for patients categorized as low risk using
the ATRIA score, there was a graded increase in the
stroke rate when subdivided by CHA2DS2-VASc scores.atients With an ATRIA Score of 0–5
ollow-Up 10-Year Follow-Up 15-Year Follow-Up
No. of
Events
Stroke
Rate Person-Years
No. of
Events
Stroke
Rate Person-Years
No. of
Events
Stroke
Rate
501 1.36 57,095 748 1.31 63,118 834 1.32
873 1.60 81,861 1,389 1.70 89,763 1,573 1.75
805 2.51 46,262 1,177 2.54 49,572 1,294 2.61
982 3.22 43,290 1,456 3.36 46,260 1,584 3.42
1,402 3.71 53,410 2,089 3.91 57,115 2,266 3.97
1,994 4.30 62,607 2,798 4.47 65,619 2,998 4.57
6,557 2.75 344,525 9,657 2.80 371,447 10,549 2.84
TABLE 3 Event Rate
ATRIA Score
Substratiﬁed
CHA2DS2-VASc ¼ 0
CHA2DS2-VASc ¼ 1
CHA2DS2-VASc ¼ 2
CHA2DS2-VASc ¼ 3
CHA2DS2-VASc ¼ 4
CHA2DS2-VASc ¼ 5
CHA2DS2-VASc ¼ 6
CHA2DS2-VASc ¼ 7
Total patients
Abbreviations as in Table 1
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FIGURE 3 Kaplan-Meier Survival Curves in Patients With
an ATRIA Score of 0 to 5 Stratiﬁed on the Basis of Their
CHA2DS2-VASc Scores (15-Year Follow-Up)
Among 73,242 patients with an ATRIA score of 0 to 5, the rate
of ischemic stroke differed signiﬁcantly among patients with
CHA2DS2-VASc scores of 0 to 7. Abbreviation as in Figure 2.
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1662The rate of ischemic stroke ranged from 1.06 to 13.33
per 100 persons-years at 1-year follow-up; 1.00 to 7.50
per 100 person-years at 5-year follow-up; 1.09 to
8.33 per 100 person-years at 10-year follow-up;
and 1.15 to 8.00 per 100 person-years at 15-year
follow-up (Table 3). A CHA2DS2-VASc score of 0 iden-
tiﬁed a truly low-risk cohort with annual event rates
at 1-, 5-, 10-, and 15-year follow-up examinations
of 1.06, 1.00, 1.09, and 1.15 per 100 person-years,
respectively.
Using a CHA2DS2-VASc score of 0 as the reference
in Cox regression analysis models, the hazard ratios
at 1-year follow-up associated with CHA2DS2-VASc
scores of 1, 2, 3, 4, 5, 6, and 7 were 1.62, 2.99, 3.93,
5.45, 6.21, 5.20, and 12.15, respectively (Table 4,
Central Illustration). The hazard ratios in predictingof Ischemic Stroke Per 100 Person-Years in AF Patients With an ATRIA
1-Year Follow-Up 5-Year Follow-Up
Person-Years
No. of
Events
Stroke
Rate Person-Years
No. of
Events
Stroke
Rate P
8,511 90 1.06 34,710 341 1.00
17,136 294 1.72 67,518 1,274 1.89
19,453 617 3.17 71,918 2,246 3.12
12,089 504 4.17 44,216 1,752 3.96
4,020 233 5.80 13,616 614 4.51
1,500 99 6.60 4,966 275 5.54
362 20 5.52 1,195 52 4.35
15 2 13.33 40 3 7.50
63,086 1,859 2.95 238,179 6,557 2.75
.ischemic stroke at 5-, 10-, and 15-year follow-up ex-
aminations associated with CHA2DS2-VASc scores are
also shown in Table 4 and the Central Illustration.
In this “low-risk” subgroup using the ATRIA score,
the c-index for CHA2DS2-VASc in predicting ischemic
stroke (0.629, 95% CI: 0.616 to 0.641) was signiﬁ-
cantly higher than that of the ATRIA score (0.593,
95% CI: 0.587 to 0.598; DeLong test, p < 0.001). The
CHA2DS2-VASc score also improved the NRI by 9.2%
compared with the ATRIA score (p < 0.0001).
DISCUSSION
In this nationwide cohort study, we demonstrated
that the CHA2DS2-VASc scoring system performed
better than the ATRIA scoring system in predicting
ischemic stroke among nonanticoagulated AF pa-
tients, as assessed by c-indexes and NRI. Even in
patients categorized as “low-risk” using an ATRIA
score of 0 to 5, the CHA2DS2-VASc score could further
reﬁne stroke risk stratiﬁcation, with improved pre-
diction for ischemic stroke on the basis of c-indexes.
A CHA2DS2-VASc score of 0 could clearly identify
truly low-risk subjects, whereas those deﬁned using
the ATRIA score were not actually low-risk patients,
with 1-year event rates ranging from 1.06 (CHA2DS2-
VASc score ¼ 0) to 13.33 (CHA2DS2-VASc score ¼ 7).
Stroke risk scoring schemes were initially devel-
oped with the goal of helping physicians to select
patients who should receive OACs after considering
the net clinical beneﬁt, balancing stroke reduction
against major bleeding, particularly with an “incon-
venient” drug, warfarin (13). The CHADS2 score was a
popular scoring system in the past 10 years because
of its simplicity in identifying “high-risk” patients.
However, the annual stroke rate was still nearly 2%
for patients with a CHADS2 score of 0, suggesting
that the CHADS2 score was inadequate in identifyingScore of 0–5 Substratiﬁed by CHA2DS2-VASc Scores
10-Year Follow-Up 15-Year Follow-Up
erson-Years
No. of
Events
Stroke
Rate Person-Years
No. of
Events
Stroke
Rate
53,486 584 1.09 59,194 683 1.15
101,103 2,044 2.02 110,854 2,312 2.09
102,566 3,354 3.27 109,810 3,659 3.33
61,620 2,473 4.01 65,050 2,636 4.05
17,795 786 4.42 18,374 830 4.52
6,463 343 5.31 6,655 354 5.32
1,444 69 4.78 1,460 71 4.86
48 4 8.33 50 4 8.00
344,525 9,657 2.80 371,447 10,549 2.84
TABLE 4 Risk of Ischemic Stroke in Patients with an ATRIA Score of 0 to 5,
Stratiﬁed on the Basis of Their CHA2DS2-VASc Scores
CHA2DS2-VASc
Score
No. of
Events Person-Years HR 95% CI p Value
1-yr follow-up
0 90 8,511 – – –
1 294 17,136 1.62 1.28–2.05 <0.001
2 617 19,453 2.99 2.40–3.73 <0.001
3 504 12,089 3.93 3.14–4.92 <0.001
4 233 4,020 5.45 4.27–6.95 <0.001
5 99 1,500 6.21 4.67–8.26 <0.001
6 20 362 5.20 3.20–8.44 <0.001
7 2 15 12.15 3.00–49.31 0.001
5-yr follow-up
0 341 34,710 – – –
1 1,274 67,518 1.92 1.70–2.16 <0.001
2 2,246 71,918 3.18 2.83–3.56 <0.001
3 1,752 44,216 4.03 3.59–4.52 <0.001
4 614 13,616 4.58 4.01–5.23 <0.001
5 275 4,966 5.63 4.80–6.59 <0.001
6 52 1,195 4.42 3.30–5.92 <0.001
7 3 40 7.53 2.43–23.34 0.001
10-yr follow-up
0 584 53,486 – – –
1 2,044 101,103 1.86 1.69–2.04 <0.001
2 3,354 102,566 3.02 2.76–3.29 <0.001
3 2,473 61,620 3.71 3.39–4.06 <0.001
4 786 17,795 4.11 3.69–4.57 <0.001
5 343 6,463 4.94 4.32–5.65 <0.001
6 69 1,444 4.48 3.49–5.76 <0.001
7 4 48 7.77 2.91–20.77 <0.001
15-yr follow-up
0 683 59,194 – – –
1 2,312 110,854 1.82 1.67–1.98 <0.001
2 3,659 109,810 2.94 2.71–3.19 <0.001
3 2,636 65,050 3.60 3.31–3.91 <0.001
4 830 18,374 4.06 3.67–4.50 <0.001
5 354 6,655 4.79 4.21–5.45 <0.001
6 71 1,460 4.44 3.48–5.67 <0.001
7 4 50 7.16 2.68–19.14 <0.001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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1663truly low-risk patients; indeed, among patients with
a low-risk CHADS2 (score ¼ 0), the stroke rate can be
as high as 3.2%/year when substratiﬁed by the
CHA2DS2-VASc score (4).
The introduction of new OACs has changed the
landscape for stroke prevention in AF, given their
relative efﬁcacy, safety, and convenience (14,15).
The use of new OACs may lower the threshold
for initiating OAC for AF patients, as the tipping point
threshold has shifted toward initiating OACs at a
stroke rate of approximately 1%/year (16), given the
positive net clinical beneﬁt of new OACs, even in
patients with a CHA2DS2-VASc score of 1 (17). Well-
controlled warfarin therapy with a high time in the
therapeutic range (>70%) has also been associated
with low rates of stroke and bleeding (18–20).
More recently, the focus has shifted toward initially
identifying patients who are truly at low risk for
ischemic stroke, in whom no antithrombotic therapy is
recommended (2,21). The CHA2DS2-VASc score has
been shown in multiple cohorts to be the best for
identifying truly low-risk patients, even in those with
a CHADS2 score of 0 (4,8). Indeed, the risk of ischemic
stroke for AF patients with a CHA2DS2-VASc score of
0 was even as low as that of non-AF patients (10).
In the present study, we found that patients
caterorized as low-risk on the basis of their ATRIA
scores were not actually at low risk, with an annual
ischemic stroke rate of 2.95% at 1-year follow-up,
which was even higher than the rate of life-
threatening bleeding with dabigatran use in the
RE-LY study (Randomized Evaluation of Long Term
Anticoagulant Therapy With Dabigatran Etexilate)
(1.22%/year for dabigatran 110 mg; 1.45%/year for
dabigatran 150 mg) (14). Thus, if we used the
ATRIA score to guide decisions for OAC therapy, a
considerable number of patients who could beneﬁt
from new OACs or well-controlled warfarin therapy
(with high time in therapeutic range) would be
denied treatment. Moreover, among low-risk pa-
tients with an ATRIA score of 0 to 5, the CHA2DS2-
VASc score could range from 0 to 7, and these
patients had stroke rates as high as 13.3 per 100
person-years (1-year follow-up). For patients with
an ATRIA score of 0, the annual risk of ischemic
stroke was 1.28%, which was higher than that of
patients with a CHA2DS2-VASc score of 0 (1.06%; 1-
year follow-up). Accordingly, the CHA2DS2-VASc
score may perform better than the ATRIA score in
identifying truly low-risk patients.
Compared with the CHA2DS2-VASc score, the ATRIA
score includes renal dysfunction (eGFR <45 ml/min or
ESRD) and proteinuria instead of vascular diseases in
the scoring system. Whether renal dysfunction is animportant risk factor with an additive role that im-
proves risk stratiﬁcation scores in AF has been the
subject of some attention. In the analysis of ROCKET
AF (Rivaroxaban Once-daily, oral, direct factor Xa in-
hibition Compared with vitamin K antagonism for
prevention of stroke and Embolism Trial in Atrial
Fibrillation) trial cohort, reduced creatinine clearance
was an independent predictor of stroke and systemic
embolism. In that anticoagulated trial cohort that
selected only high-risk AF patients for study and
excluded those with severe renal failure, a risk model
including creatinine clearance could improve NRI by
6.2% compared with CHA2DS2-VASc and by 8.2%
compared with CHADS2 (22). Subsequent studies with
a broader range of AF stroke risk and renal dysfunction
CENTRAL ILLUSTRATION Risk of Ischemic Stroke in Patients With an ATRIA Score of 0 to 5 Stratiﬁed Based on Their ATRIA and
CHA2DS2-VASc Scores
Hazard ratios of ischemic stroke increased continuously for patients with a CHA2DS2-VASc score of 1 to 7 compared to those with a CHA2DS2-
VASc score of 0. A similar trend was also noted for patients with an ATRIA score of 1-5 compared to those with an ATRIA score of 0. ATRIA ¼
anticoagulation and risk factors in atrial ﬁbrillation; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75, diabetes mellitus, prior
stroke or transient ischemic attack, vascular disease, age 65 to 74, female; CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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1664have not conﬁrmed an additive impact of renal
impairment to stroke prediction using the CHA2DS2-
VASc or CHADS2 score (23–25). The ATRIA score assigns
1 point for ESRD patients, and because new OACs are
contraindicated in patients with severe renal
dysfunction, use of the ATRIA score to determine the
strategy of stroke prevention in the era of new OACs
may perhaps be suboptimal. Another unique charac-
teristic of the ATRIA scheme was that it calculated
scores for patients with or without prior stroke by us-
ing different rules (i.e., different weighting for risk),
and the inconvenient calculation process may prohibit
its widespread acceptance.
STUDY LIMITATIONS. Our study is the ﬁrst
population-based investigation comparing the per-
formances of ATRIA and CHA2DS2-VASc scores for
stroke prediction in nonanticoagulated AF patients.
The strength of our study is the use of a nationwide
dataset, which enrolled a large sample of subjects.
However, some limitations are still evident. First, pre-
cise data about eGFR were not recorded in this reg-
istry database. Thus, we used the diagnosis of chronic
kidney disease to represent eGFR of <45 ml/min
for calculation of the ATRIA score. Because the diag-
nosis of chronic kidney disease in our database may
not be adequately sensitive, a signiﬁcant number
of individuals with reduced eGFR could be missedand were potentially misclassiﬁed by ATRIA score
as low-risk patients. Second, the types of AF (parox-
ysmal or nonparoxysmal) were not available from
this nationwide dataset. Because the risk of stroke
does not differ between patients with paroxysmal
and those with nonparoxysmal AF (26), the type of
AF would not confound the ﬁndings of this study.
Third, because the present study enrolled only Asian
patients, whether the results can be extrapolated
to non-Asian population remains uncertain.
CONCLUSIONS
In this real-world nationwide AF cohort study, we
demonstrated that the CHA2DS2-VASc score performs
better than the ATRIA scoring system in predicting
ischemic stroke. Importantly, patients categorized
as “low-risk” using the ATRIA score were not neces-
sarily at low risk, and annual stroke rates can be as high
as 2.95% at 1-year follow-up and 2.84% at 15-year
follow-up. In contrast, patients with a CHA2DS2-VASc
score of 0 had a truly low risk of ischemic stroke.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The CHA2DS2-
VASc score performed better than the ATRIA score in predict-
ing ischemic stroke in AF patients, as assessed by the c-statistic
and net reclassiﬁcation index.
COMPETENCY IN PATIENT CARE: The CHA2DS2-VASc
score may be used for stroke risk stratiﬁcation in Asian patients
with atrial ﬁbrillation.
TRANSLATIONAL OUTLOOK: Additional research is
needed to determine whether incorporation of additional risk
factors, including validated biomarkers, could further reﬁne
clinical risk stratiﬁcation for patients with atrial ﬁbrillation.
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